Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more

E-poster session
Chairs: M. Molina Molina (Barcelona, Spain), V. Cottin (Lyon, France)

A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), S. Si-Mohamed (Lyon, France), K. Ahmad (Lyon, France), L. Boussel (Lyon, France), M. Brevet (Lyon, France), L. Chalabreysse (Lyon, France), C. Fabre (Bordeaux, France), S. Marque (Bordeaux, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), J. Traclet (Lyon, France), S. Zeghmar (Lyon, France), D. Maucort-Boulch (Lyon, France), V. Cottin (Lyon, France)
Progressive fibrosing interstitial lung diseases (PF-ILDs): prevalence and characterization in two Italian referral centers P. Faverio (Monza, Italy), R. Cassandro (Milano, Italy), M. Piluso (Monza, Italy), F. De Giacomi (Monza, Italy), M. Della Zoppa (Monza, Italy), S. Harari (Milano, Italy), F. Luppi (Monza, Italy), A. Pesci (Monza, Italy)
The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. T. Simpson (London, United Kingdom), A. West (London, United Kingdom)
Baseline CT thorax fibrosis using a cutoff of 10% alone does not portend a poorer prognosis in non-IPF ILD M. Kam (Singapore, Singapore), Y. Tan (Singapore, Singapore), S. Low (Singapore, Singapore)
Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), L. Boussel (Lyon, France), S. Si-Mohamed (Lyon, France), F. Diaz (Bordeaux, France), S. Marque (Bordeaux, France), J. Massol (Bordeaux, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), L. Chalabreysse (Lyon, France), D. Maucort-Boulch (Lyon, France), V. Cottin (Lyon, France)
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype M. Kokosi (London, United Kingdom), A. Trachalaki (London, United Kingdom), C. Stock (London, United Kingdom), J. Donovan (London, United Kingdom), E. Tsitoura (Herakleion, Greece), V. Kouranos (Londonn, United Kingdom), P. George (Londonn, United Kingdom), P. Molyneaux (Londonn, United Kingdom), F. Chua (Londonn, United Kingdom), T. Maher (Londonn, United Kingdom), E. Renzoni (Londonn, United Kingdom), N. Tzanakis (Herakleion, Greece), A. Wells (London, United Kingdom), K. Antoniou (Herakleion, Greece)
Telomere-Related Gene mutations in a Greek cohort of suspected monogenic pulmonary fibrosis patients E. Manali (Athens, Greece), C. Kannengiesser (Paris, France), R. Borie (Paris, France), I. Ba (Paris, France), D. Bouros (Athens , Greece), V. Tzilas (Athens , Greece), A. Tzouvelekis (Athens , Greece), E. Bouros (Athens , Greece), A. Markopoulou (Thessaloniki, Greece), K. Antoniou (Heraklion , Greece), A. Trachalaki (Heraklion , Greece), L. Kolilekas (Athens , Greece), Z. Daniil (Larissa, Greece), E. Fouka (thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece), A. Xyfteri (Messini, Greece), I. Korbila (Athens , Greece), A. Papaioannou (Athens , Greece), I. Tomos (Athens , Greece), A. Karakatsani (Athens , Greece), S. Loukides (Athens , Greece), K. Kagouridis (Athens , Greece), A. Gogali (Ioannina , Greece), A. Konstantinidis (Ioannina , Greece), P. Steiropoulos (Alexandroupolis, Greece), I. Papanikolaou (Corfu , Greece), C. Bazaka (Agrinio, Greece), A. Haritou (Ioannina , Greece), M. Maniati (Ioannina , Greece), T. Vassilakopoulos (Athens , Greece), E. Markozannes (Athens , Greece), P. Lyberopoulos (Athens , Greece), N. Malamadakis (Athens , Greece), S. Spyropoulou (Chalkis, Greece), P. Revy (Paris, France), E. Lainey (Paris, France), P. Dieudé (Paris, France), N. Nathan (Paris, France), M. Legendre (Paris, France), K. Rebah (Paris, France), C. Ménard (Paris, France), C. Oudin (Paris, France), C. Boileau (Paris, France), B. Crestani (Paris, France), S. Papiris (Athens , Greece)
Study of IPF relatives as a method of early diagnosis of ILD disease O. Bronte Moreno (Galdakao, Spain), M. Aburto (Galdakao, Spain), A. Urrutia (Barakaldo, Spain), C. Jaca (Barakaldo, Spain), M. Arrizubieta (Galdakao, Spain), M. Salinas (Bilbao, Spain), L. Tomás (Vitoria, Spain), I. Salegui (Donostia, Spain)
A family history of ILD is a significant risk factor for worse transplant-free survival in IPF patients T. Goos (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
The study of telomere associated genes and telomere measurement in Idiopathic Pulmonary Fibrosis H. Yildirim (Istanbul, Turkey), B. Yildiz (Istanbul, Turkey), E. Coskunpinar (Istanbul, Turkey)
Clinical characteristics and prognosis of fibrotic nonspecific interstitial pneumonia H. Cho (Seoul, Republic of Korea), H. Yoo (Seoul, Republic of Korea), S. Wi (Seoul, Republic of Korea), K. Lee (Seoul, Republic of Korea), M. Chung (Seoul, Republic of Korea), J. Han (Seoul, Republic of Korea), M. Chung (Seoul, Republic of Korea)
Extracellular HSP90a promotes cellular senescence in pulmonary fibrosis through TGFß signaling H. Dong (Guangzhou (Guangdong), China), W. Zhong (Guangzhou (Guangdong), China), J. Zhang (Guangzhou (Guangdong), China), Y. Liu (Guangzhou (Guangdong), China), W. Chen (Guangzhou (Guangdong), China), C. Ye (Guangzhou (Guangdong), China), X. Wan (Guangzhou (Guangdong), China), S. Cai (Guangzhou (Guangdong), China)
Extracellular HSP90a promotes pulmonary fibrosis by impairing autophagic flux in lung fibroblasts H. Dong (Guangzhou (Guangdong), China), J. Zhang (Guangzhou (Guangdong), China), W. Zhong (Guangzhou (Guangdong), China), W. Chen (Guangzhou (Guangdong), China), Y. Liu (Guangzhou (Guangdong), China), X. Wan (Guangzhou (Guangdong), China), C. Ye (Guangzhou (Guangdong), China), S. Cai (Guangzhou (Guangdong), China)
Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung M. Jia (Pittsburgh, United States of America), M. Kapetanaki (Pittsburgh, United States of America), T. Cruz (Pittsburgh, United States of America), T. Tabib (Pittsburgh, United States of America), A. Mora (Pittsburgh, United States of America), R. Lafyatis (Pittsburgh, United States of America), M. Rojas (Pittsburgh, United States of America), P. Benos (Pittsburgh, United States of America)
Effects of a TRPV4 antagonist and pirfenidone on idiopathic pulmonary fibrosis K. Kuronuma (Sapporo, Japan), M. Wakabayashi (Toyonaka, Japan), T. Yoshioka (Toyonaka, Japan), T. Kobayashi (Sapporo, Japan), M. Kameda (Sapporo, Japan), M. Otsuka (Sapporo, Japan), H. Chiba (Sapporo, Japan), H. Takahashi (Sapporo, Japan)
Cigarette-decreased NAD/SIRT1 aggravates pulmonary fibrosis by promoting senescence of alveolar type 2 cells through autophagy inhibition and mitochondrial oxidative stress induction Y. Zhang (Guangzhou, China), Y. Meng (Guangzhou, China)
LSC - 2020 - Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis patients A. Martin (Palma, Spain)
Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis A. Martin (Palma, Spain), A. Jahn (Palma, Spain), C. Rio (Palma, Spain), A. Iglesias (Palma, Spain), J. Mercader (Palma, Spain), A. Montes (Bellvitge, Spain), C. Crespi (Palma, Spain), J. Pons (Palma, Spain), J. Velasco (Palma, Spain), C. Villena (Palma, Spain), A. Carvajal (Palma, Spain), O. Gigirey (Palma, Spain), L. Elowson (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden), M. Molina (Bellvitge, Spain), E. Sala-Llinas (Palma, Spain)